Manuel Romero-Gómez-rekin lankidetzan egindako argitalpenak (8)

2024

  1. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR–MASH score

    Liver International, Vol. 44, Núm. 1, pp. 202-213

2023

  1. Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 967-976

2022

  1. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis

    Journal of Hepatology, Vol. 77, Núm. 6, pp. 1554-1563

2018

  1. Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression

    Journal of Gastroenterology and Hepatology (Australia), Vol. 33, Núm. 3, pp. 718-725

2015

  1. Minimal Hepatic Encephalopathy and Critical Flicker Frequency Are Associated with Survival of Patients with Cirrhosis

    Gastroenterology, Vol. 149, Núm. 6, pp. 1483-1489

2010

  1. Serum metabolic signature of minimal hepatic encephalopathy by 1H-nuclear magnetic resonance

    Journal of Proteome Research, Vol. 9, Núm. 10, pp. 5180-5187

  2. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: A cohort study

    Annals of Internal Medicine, Vol. 153, Núm. 5, pp. 281-288

2007

  1. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy

    Hepatology, Vol. 45, Núm. 4, pp. 879-885